188 related articles for article (PubMed ID: 28101701)
1. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.
Merkel A; Soeldner D; Wendl C; Urkan D; Kuramatsu JB; Seliger C; Proescholdt M; Eyupoglu IY; Hau P; Uhl M
J Neurooncol; 2017 Apr; 132(2):249-254. PubMed ID: 28101701
[TBL] [Abstract][Full Text] [Related]
2. The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated
Choi YS; Ahn SS; Lee HJ; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
AJNR Am J Neuroradiol; 2017 Aug; 38(8):1528-1535. PubMed ID: 28642265
[TBL] [Abstract][Full Text] [Related]
3. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
[TBL] [Abstract][Full Text] [Related]
4. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
[TBL] [Abstract][Full Text] [Related]
5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
6. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
[TBL] [Abstract][Full Text] [Related]
7. Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma.
Adeberg S; Bostel T; Harrabi S; Bernhardt D; Welzel T; Wick W; Debus J; Combs SE
BMC Cancer; 2015 Jul; 15():558. PubMed ID: 26223282
[TBL] [Abstract][Full Text] [Related]
8. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
9. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
11. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
12. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
13. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.
Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A
J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716
[TBL] [Abstract][Full Text] [Related]
15. Noninvasive O
Hajianfar G; Shiri I; Maleki H; Oveisi N; Haghparast A; Abdollahi H; Oveisi M
World Neurosurg; 2019 Dec; 132():e140-e161. PubMed ID: 31505292
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Roles of Gender and O6-Methylguanine-DNA Methyltransferase Methylation Status in Glioblastoma Patients: The Female Power.
Franceschi E; Tosoni A; Minichillo S; Depenni R; Paccapelo A; Bartolini S; Michiara M; Pavesi G; Urbini B; Crisi G; Cavallo MA; Tosatto L; Dazzi C; Biasini C; Pasini G; Balestrini D; Zanelli F; Ramponi V; Fioravanti A; Giombelli E; De Biase D; Baruzzi A; Brandes AA;
World Neurosurg; 2018 Apr; 112():e342-e347. PubMed ID: 29337169
[TBL] [Abstract][Full Text] [Related]
17. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
Takeuchi S; Wada K; Toyooka T; Shinomiya N; Shimazaki H; Nakanishi K; Nagatani K; Otani N; Osada H; Uozumi Y; Matsuo H; Nawashiro H
Neurosurgery; 2013 Jan; 72(1):33-41; discussion 41. PubMed ID: 23096413
[TBL] [Abstract][Full Text] [Related]
18. Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma.
Choi YS; Ahn SS; Kim DW; Chang JH; Kang SG; Kim EH; Kim SH; Rim TH; Lee SK
Radiology; 2016 Oct; 281(1):175-84. PubMed ID: 27120357
[TBL] [Abstract][Full Text] [Related]
19. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
20. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
